Research published in the United European Gastroenterology Journal suggests that Cellvizio, a probe-based confocal laser endomicroscopy system from Mauna Kea Technologies, can improve the diagnosis and management of a number of GI conditions, according to an IBD News Today report.
The study identifies Barrett’s esophagus, colorectal lesions, inflammatory bowel disease, pancreatic cysts, biliopancreatic strictures and gastric diseases as conditions that could be benefit from the use of Cellvizio.
The technology form Mauna Kea hold both FDA 510(k) clearance and a European CE Mark.
More articles on gastroenterology:
Zacks reiterates Boston Scientific’s “neutral” rating
23 gastroenterologists making headlines
Smoking increases mortality risk in colorectal cancer patients
In healthcare’s dynamic regulatory and economic environment, leaders of gastroenterology-focused ASCs are keeping close tabs on industry developments. Here are…
Approximately 1 in 26 women will be diagnosed with colorectal cancer in their lifetime. Despite this, many women may mistake…
Gastroenterologists are facing increasing financial strain as reimbursement rates continue to decline. A study published in The American Journal of…
